Johan Diderik Boot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Johan Diderik Boot has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ronald van Ree
Department of experimental immunology Amsterdam University Medical Centers Amsterdam the Netherlands
2 shared publications - Andreas Distler
HAL Allergie GmbH, 40213 Düsseldorf, Germany
1 shared publication - Annette Sperl
Zentrum Rhinol & Allergol, Quellen 10, D-65183 Wiesbaden, Germany
1 shared publication - Esther van Twuijver
HAL Allergy BV, Medical Department, Leiden, The Netherlands
1 shared publication - Huub Kleinjans
HAL Allergy BV, Medical Department, Leiden, The Netherlands
1 shared publication - Juliane Rieker‐Schwienbacher
Klinikum Stuttgart, Klinik für Dermatologie und Allergologie, Priessnitzweg 24, Stuttgart, Germany
1 shared publication
Latest Publications
- Open Access
- 1 January 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (1) , 23
A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations
Background: SUBLIVAC FIX Birch (SUB‐B) is a liquid oral preparation of Betula verrucosa pollen extract for the treatment of allergic rhinitis/rhinoconjuctivitis induced by birch pollen. The major allergen content of SUB‐B and Staloral Birch (Stal‐B) have been shown to be comparable. In order to compare the clinical efficacy and safety of both products, the present study was designed to investigate efficacy of treatment with SUB‐B compared to Stal‐B by means of reduction in allergy symptoms assessed by a titrated nasal provocation test (TNPT) in subjects suffering from IgE mediated allergy complaints triggered by birch pollen.Methods: A prospective, randomized, open, blinded endpoint (PROBE), controlled, single‐centre study in 74 birch allergic adults was performed. Treatment consisted of either SUB‐B (10,000 AUN/ml) or Stal‐B (initial phase 10 I.R./ml and maintenance phase 300 I.R./ml) for 16–20 weeks at maintenance dose. The primary efficacy outcome was defined by the difference in change of the TNPT‐threshold dose between the two treatment groups at baseline and after completion of treatment. Secondary outcomes included determination of birch pollen specific IgE and IgG levels, safety lab and ECG. During the first 30 days of treatment, subjects were requested to fill out a diary concerning compliance with study medication, occurrence of AEs and the use of concomitant medication.Results: Analysis of the primary efficacy parameter showed that the percentage of subjects showing a beneficial treatment effect was similar in both treatment groups, 33.3% for SUB‐B vs. 31.4% for Stal‐B in the intention to treat population. Evaluation of the immunologic response, showed that treatment with SUB‐B and Stal‐B induced similar increases (approximately 2 times) in IgE, IgG and IgG4 specific for Bet v 1.In total, 143 related adverse events (AEs) were reported. The majority of the AEs was of mild intensity. The same pattern of AEs was observed for both products. No clinically relevant changes in other safety parameters, such as safety laboratory parameters, vital signs, physical examination and ECGs were observed.Conclusion: Taken together, treatment with both products was effective by means of reduction in allergic symptoms during a TNPT. In addition, safety analysis revealed a good tolerability of both SLIT extracts.
- 1 January 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (1) , 23
Open AccessA prospective study comparing the efficacy and safety of two sublingual birch allergen preparations
Background: SUBLIVAC FIX Birch (SUB‐B) is a liquid oral preparation of Betula verrucosa pollen extract for the treatment of allergic rhinitis/rhinoconjuctivitis induced by birch pollen. The major allergen content of SUB‐B and Staloral Birch (Stal‐B) have been shown to be comparable. In order to compare the clinical efficacy and safety of both products, the present study was designed to investigate efficacy of treatment with SUB‐B compared to Stal‐B by means of reduction in allergy symptoms assessed by a titrated nasal provocation test (TNPT) in subjects suffering from IgE mediated allergy complaints triggered by birch pollen.Methods: A prospective, randomized, open, blinded endpoint (PROBE), controlled, single‐centre study in 74 birch allergic adults was performed. Treatment consisted of either SUB‐B (10,000 AUN/ml) or Stal‐B (initial phase 10 I.R./ml and maintenance phase 300 I.R./ml) for 16–20 weeks at maintenance dose. The primary efficacy outcome was defined by the difference in change of the TNPT‐threshold dose between the two treatment groups at baseline and after completion of treatment. Secondary outcomes included determination of birch pollen specific IgE and IgG levels, safety lab and ECG. During the first 30 days of treatment, subjects were requested to fill out a diary concerning compliance with study medication, occurrence of AEs and the use of concomitant medication.Results: Analysis of the primary efficacy parameter showed that the percentage of subjects showing a beneficial treatment effect was similar in both treatment groups, 33.3% for SUB‐B vs. 31.4% for Stal‐B in the intention to treat population. Evaluation of the immunologic response, showed that treatment with SUB‐B and Stal‐B induced similar increases (approximately 2 times) in IgE, IgG and IgG4 specific for Bet v 1.In total, 143 related adverse events (AEs) were reported. The majority of the AEs was of mild intensity. The same pattern of AEs was observed for both products. No clinically relevant changes in other safety parameters, such as safety laboratory parameters, vital signs, physical examination and ECGs were observed.Conclusion: Taken together, treatment with both products was effective by means of reduction in allergic symptoms during a TNPT. In addition, safety analysis revealed a good tolerability of both SLIT extracts.
- Open Access
- 1 January 2013
- Published by Wiley in Clinical and Translational Allergy
- Vol. 3 (1) , 16
Open‐label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients
Background: The current maintenance dose (10,000 AUeq/monthly) of a subcutaneous allergoid for house dust mite (HDM) immunotherapy has previously shown significant clinical efficacy in patients with HDM induced allergic rhinitis or rhinoconjunctivitis. In order to comply with the 2009 EMA guidelines on immunotherapy products, a study was conducted to evaluate the safety, tolerability and short‐term treatment effects of up‐dosing regimens with high doses (up to 40,000 AUeq) of allergoid HDM immunotherapy.Methods: In total 48 patients with HDM‐allergic rhinitis or rhinoconjunctivitis (29 M/19 F; 18–53 years) were included and enrolled into one of three up‐dosing regimens (1:4:4): 1) a regular regimen with up‐dosing to 40,000 AUeq followed by two maintenance doses (total duration 17 weeks), 2) an intermediate regimen (14 weeks) or 3) a fast regimen (11 weeks). Safety and tolerability were evaluated by monitoring of early and late local reactions and systemic reactions. In addition, short‐term effects were assessed by conjunctival provocation test (CPT) and levels of serum allergen‐specific IgE, IgG and IgG4.Results: Thirty‐nine patients completed the study according to protocol. No early local reactions occurred. Late local reactions (LLR) were observed in 12% of the injections. In total, 31 systemic reactions, all grade 1, were reported of which two needed oral antihistamine treatment. No grade 2 or higher systemic reactions were observed. Six patients (15%) did not reach the highest dose due to LLR and/or systemic reactions needing antihistamines (20% in the regular regimen, 16% in the intermediate regimen and 13% in the fast regimen). At the end of the study, an improvement in the CPT was observed in 82.1% of patients, indirectly indicating an early treatment effect at the current dose and higher doses. In addition, IgG4 immunoglobulin levels were significantly increased in all groups following treatment.Conclusions: In this open‐label study, allergoid HDM immunotherapy in doses up to 40,000 AUeq was generally well tolerated and no clinically relevant safety issues were identified. In the safety aspects of the three up‐dosing regimens no clinically relevant differences were encountered. Therefore, these dose ranges and up‐dosing regimens can be safely included in future dose‐finding efficacy studies.
- 1 January 2013
- Published by Wiley in Clinical and Translational Allergy
- Vol. 3 (1) , 16
Open AccessOpen‐label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients
Background: The current maintenance dose (10,000 AUeq/monthly) of a subcutaneous allergoid for house dust mite (HDM) immunotherapy has previously shown significant clinical efficacy in patients with HDM induced allergic rhinitis or rhinoconjunctivitis. In order to comply with the 2009 EMA guidelines on immunotherapy products, a study was conducted to evaluate the safety, tolerability and short‐term treatment effects of up‐dosing regimens with high doses (up to 40,000 AUeq) of allergoid HDM immunotherapy.Methods: In total 48 patients with HDM‐allergic rhinitis or rhinoconjunctivitis (29 M/19 F; 18–53 years) were included and enrolled into one of three up‐dosing regimens (1:4:4): 1) a regular regimen with up‐dosing to 40,000 AUeq followed by two maintenance doses (total duration 17 weeks), 2) an intermediate regimen (14 weeks) or 3) a fast regimen (11 weeks). Safety and tolerability were evaluated by monitoring of early and late local reactions and systemic reactions. In addition, short‐term effects were assessed by conjunctival provocation test (CPT) and levels of serum allergen‐specific IgE, IgG and IgG4.Results: Thirty‐nine patients completed the study according to protocol. No early local reactions occurred. Late local reactions (LLR) were observed in 12% of the injections. In total, 31 systemic reactions, all grade 1, were reported of which two needed oral antihistamine treatment. No grade 2 or higher systemic reactions were observed. Six patients (15%) did not reach the highest dose due to LLR and/or systemic reactions needing antihistamines (20% in the regular regimen, 16% in the intermediate regimen and 13% in the fast regimen). At the end of the study, an improvement in the CPT was observed in 82.1% of patients, indirectly indicating an early treatment effect at the current dose and higher doses. In addition, IgG4 immunoglobulin levels were significantly increased in all groups following treatment.Conclusions: In this open‐label study, allergoid HDM immunotherapy in doses up to 40,000 AUeq was generally well tolerated and no clinically relevant safety issues were identified. In the safety aspects of the three up‐dosing regimens no clinically relevant differences were encountered. Therefore, these dose ranges and up‐dosing regimens can be safely included in future dose‐finding efficacy studies.